Evidence map›Paper›PMID 33089069›Full record

ArticleBMC rheumatology2020

Ultrasound and multi-biomarker disease activity score for assessing and predicting clinical response to tofacitinib treatment in patients with rheumatoid arthritis.

Amir A Razmjou, Jenny Brook, David Elashoff, Gurjit Kaeley, Soo Choi, Tanaz Kermani, Veena K Ranganath

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC rheumatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02321930 (Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients), which is not on this map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02321930 phase4completednot on this map

Musculoskeletal Ultrasound Assessment of Therapeutic Response of Tofacitinib in Rheumatoid Arthritis Patients

TypeinterventionalSponsorUniversity of California, Los AngelesRan2016 to 2017Enrolled37ConditionsRheumatoid ArthritisArmstofacitinib 5mg po bid
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Efficacy of Janus kinase inhibitors in rheumatoid arthritis.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2023
    Review
  11. Review
  12. Article
  13. Observational
  14. Article
  15. Article
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Amir A RazmjouDepartment of Medicine, UCLA-David Geffen School of Medicine, Los Angeles, USA.ORCID https://orcid.org/0000-0002-5245-3998
Jenny BrookDepartment of Medicine Statistics Core, UCLA-David Geffen School of Medicine, Los Angeles, USA.
David ElashoffDepartment of Medicine Statistics Core, UCLA-David Geffen School of Medicine, Los Angeles, USA.
Gurjit KaeleyDepartment of Rheumatology, University of Florida Health, Jacksonville, USA.
Soo ChoiDepartment of Rheumatology, University of California, San Diego, USA.
Tanaz KermaniDepartment of Rheumatology, UCLA-David Geffen School of Medicine, 1000 Veteran Blvd., RM 32-59, Los Angeles, CA 90095 USA.
Veena K RanganathDepartment of Rheumatology, UCLA-David Geffen School of Medicine, 1000 Veteran Blvd., RM 32-59, Los Angeles, CA 90095 USA.ORCID https://orcid.org/0000-0003-3417-9478
University of California, Los Angeles · USUniversity of California San Diego · USUniversity of Florida Health · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMusculoskeletal ultrasound (MSUS) and the multi-biomarker disease activity (MBDA) score are outcome measures that may aid in the management of rheumatoid arthritis (RA) patients. This study evaluated tofacitinib response by MSUS/MBDA scores and assessed whether baseline MSUS/MBDA scores or their early changes predict later clinical response.

methodsTwenty-five RA patients treated with tofacitinib were assessed at baseline, 2, 6 and 12-weeks. Power doppler (PDUS) and gray scale (GSUS) ultrasound scores, MBDA score, clinical disease activity index (CDAI), and disease activity score (DAS28) were obtained. Pearson correlations and multiple linear regression models were used to evaluate associations and identify predictors of response to therapy.

resultsMSUS, MBDA scores, CDAI, and DAS28 improved significantly over 12 weeks (

conclusionsRA patients treated with tofacitinib for 12 weeks demonstrated improvement by clinical, imaging, and biomarker end-points. Baseline PDUS and MBDA score were predictive of CDAI and DAS28 responses. This is the first study to evaluate early measurements of MSUS and MBDA score as predictors of clinical response in RA patients treated with tofacitinib.

trial registrationClinicalTrials.gov NCT02321930 (registered 12/22/2014).

Indexed as

Multi-biomarker disease activity scoreOutcome measuresRheumatoid arthritisUltrasound

Identifiers

PMID33089069
PMCPMC7569763
OpenAlexW3093702445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.